Yesterday, a Director at Veracyte (VCYT), Evan Fa Jones, sold shares of VCYT for $1.53M.
Following Evan Fa Jones’ last VCYT Sell transaction on May 29, 2018, the stock climbed by 13.2%. In addition to Evan Fa Jones, one other VCYT executive reported Sell trades in the last month.
See today’s analyst top recommended stocks >>
Based on Veracyte’s latest earnings report for the quarter ending December 31, the company posted quarterly revenue of $25.75 million and GAAP net loss of $3.11 million. In comparison, last year the company earned revenue of $19.6 million and had a GAAP net loss of $8.44 million. Currently, Veracyte has an average volume of 1.16M. The Company has a Price to Book ratio of 10.6161.
The insider sentiment on Veracyte has been negative according to 22 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.
Evan Fa Jones’ trades have generated a 17.9% average return based on past transactions. DailyInsider proprietary algorithm detects trades by the most influential insiders and selects attractive trading opportunities daily. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Veracyte, Inc. engages in the research, development, and commercialization of diagnostic products. Its portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis.
